Tag Archives: Venture Capital

Atlas Cranks It Up To Eleven: Fund XI
June 29, 2017

Today we announced the closing of Atlas Venture Fund XI, a $350M investment vehicle focused exclusively on early stage biotech investing. Since launching our fundraising process in April, we’ve received a truly humbling level of support and interest in our

1 Comment

Data Snapshot: Venture-Backed Biotech Financing Riding High
April 21, 2015

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Leave a comment

Acquisitions As The Silent Partner In Biotech Liquidity: IPO vs M&A Exit Paths
October 27, 2014

With the biotech IPO window still open for business, and valuations of the recent classes of 2013 and 2014 remaining robust, all eyes have been focused on this part of the value chain.  Significant mezzanine pre-IPO rounds are getting done

2 Comments

Early Stage Biotech Venture Scarcity: Fitness, Fear, And Greed
September 22, 2014

The ever-shrinking number of biotech venture capital firms was a common refrain during the 2008-2012 period; it’s true that a large number of firms went under, closed their doors for new investments, or moved into zombie status.  I wrote on

4 Comments

Tradeoffs and Timing: IPO vs. M&A Decision Making in Biotech
April 2, 2014

In light of the continued interest in biotech IPOs by the capital markets, there’s probably not a venture-backed biotech boardroom that hasn’t been discussing the merits of going public. Whether warranted or not, taking a company public via an IPO

1 Comment

Biotech IPO Returns: Great, Good, And Not So Good
February 10, 2014

The biotech IPO bonanza appears to be continuing into 2014, with over thirteen offerings already this year.  We’re just now completing the busiest two week period in biotech IPOs ever.  Another dozen or so companies appear likely to price IPOs

Leave a comment

Correlation’s Fresh Look At Venture Capital Returns
November 18, 2013

The broad underperformance of the venture capital asset class during the past decade is widely discussed; there’s a frequently-cited assertion that U.S. venture returns trailed the overall public equity stock market in the 2000s. Few if any published analyses have

11 Comments

Biotech IPOs: The Exit Challenge As Lockups Expire
October 31, 2013

Six months ago the biotech industry was on the verge of a sizzling season for IPOs, and since then, on average, we’ve seen one new biotech IPO per week.  Valuations of many of these offerings have been impressive, and this

2 Comments

What’s Behind The Booming Biotech IPO Market
September 23, 2013

Biotech is back with a vengeance in this IPO window.  After a decade drought, we’ve witnessed over 30 new biotech offerings this year and more than $2.5B raised – the best IPO market since 2000.  In fact, it’s already the

2 Comments

VC-backed Biotech Holding Periods: Tortoise or Hare?
May 8, 2013

Biotech just takes too long, especially when compared to the overnight success of technology ventures, or so the oft-cited criticism of venture-backed biotech’s perceived longer holding period goes. Despite being a well-accepted belief  held by most venture professionals, LP’s, and

10 Comments

Favorable 1H2011 Biotech M&A Trends
August 11, 2011

Our friends at HBM Partners just published their quarterly Biotech/Pharma M&A report.  Its got some good nuggets of data in it about 1H2011. Although its hard to think about in the midst of the Great August Rollercoaster in the markets,

Leave a comment